{
    "nct_id": "NCT03164057",
    "official_title": "A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia",
    "inclusion_criteria": "INCLUSION CRITERIA:\n\n* Diagnostic criteria: Patients must have one of the following diagnoses:\n\n  * Acute myeloid leukemia fulfilling the criteria of the WHO Classification (see Appendix I), or\n  * >5% but < 20% marrow myeloblasts and evidence of a clonal de novo AML genetic abnormality [e.g., t(8;21), inv(16), t(9;11)], or\n  * Myeloid sarcoma (also referred to as extramedullary myeloid tumor, granulocytic sarcoma, or chloroma), with or without evidence of a leukemia process in the bone marrow or peripheral blood, with confirmation of myeloid differentiation, or\n  * High grade myelodysplastic syndrome (MDS) with greater than 5% blasts, or\n  * Patients with treatment related myeloid neoplasms including AML and MDS, provided their cumulative anthracycline dose has not exceeded 230 mg/m2 doxorubicin equivalents.\n* Other criteria - Patients must meet all the following criteria:\n\n  * Age > 28 days and < 22 years at time of study entry inclusive, and\n  * No prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or less for hyperleukocytosis), and\n  * Written informed consent according to institutional guidelines, and\n  * Female patients of childbearing potential must have a negative pregnancy test within 2 weeks prior to enrollment, and\n  * Male and female participants of reproductive potential must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.\n\nEXCLUSION CRITERIA:\n\n* Down syndrome\n* Acute promyelocytic leukemia (APL)\n* BCR-ABL1 chronic myeloid leukemia in blast crisis (CML-BC)\n* Juvenile myelomonocytic leukemia (JMML)\n* Fanconi anemia (FA)\n* Kostmann syndrome\n* Shwachman syndrome\n* Other bone marrow failure syndromes or low grade (<5% bone marrow blasts) MDS.\n* Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.\n* Use of investigational agents within 30 days or any anticancer therapy for this malignancy within 2 weeks before study entry with the exception of IT therapy, hydroxyurea, or low-dose cytarabine as specified in the protocol document. The patient must have recovered from all acute toxicities from any previous therapy.\n* Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).\n* Pregnant or lactating.\n* Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.\n* Prior chemotherapy, with the exception of hydroxyurea or low-dose cytarabine as specified in the protocol document. The patient must have recovered from all acute toxicities from any previous therapy.\n* Patients with treatment related myeloid neoplasms with cumulative anthracyclines greater than 230 mg/m2 doxorubicin equivalents.\nHealthy volunteers allowed\nMust have minimum age of 29 Days\nMust have maximum age of 21 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}